-+ 0.00%
-+ 0.00%
-+ 0.00%

MEDICUS PHARMA RECEIVES FDA “STUDY MAY PROCEED” LETTER FOR NDA-ENABLING REGISTRATIONAL SKINJECT® STUDY IN PATIENTS WITH GORLIN SYNDROME

Reuters·07/27/2026 12:17:00

Please log in to view news